ImmunoCellular Therapeutics, Ltd. (IMUC) Information Request Form

Levi & Korsinsky announces the commencement of a class action lawsuit in the United States District Court for the Central District of California on behalf of shareholders of ImmunoCellular Therapeutics, Ltd. (NYSEMKT : IMUC) who purchased shares between May 1, 2012 and December 11, 2013.

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; (2) as a result of this scheme, the market was led to believe that ImmunoCellular's clinical studies for its product candidate ICT-107 was going well and the Company's share price was artificially inflated.

On April 10, 2017, the Securities and Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that had engaged in stock promotion schemes.

If you suffered a loss in ImmunoCellular Therapeutics, Ltd. you have until June 30, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

To receive more information, please fill out the form.

Levi & Korsinsky, LLP doesn't share your information with others. There is no cost or obligation to submit. Your submission does NOT establish an attorney-client relationship.

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

This letter confirms that you have retained Levi & Korsinsky, LLP to represent you as a named plaintiff in a shareholder action involving ImmunoCellular Therapeutics, Ltd.

We agree to advance all expenses in the litigation, which means that you are not liable to pay any of the expenses of the lawsuit, whether attorneys' fees or costs. Regardless of the result, we will never ask you to directly pay for any attorneys' fees or costs. Should we obtain a favorable result, we may ask the court to award us compensation to be paid by the defendants or as a portion of any class benefit, but, again, we will never ask you to directly pay any of the costs of this litigation.

As the client you are entitled to direct the litigation in any way you deem proper, and may at any time order us to dismiss the case or opt-out. Should you choose to do so, we will never ask you to reimburse us directly for any legal fees or expenses. During the course of this litigation, we may employ and/or work with other law firms to prosecute your case.

We look forward to representing you and other ImmunoCellular Therapeutics, Ltd. shareholders.


Levi & Korsinsky,LLP

Joseph Levi

AGREED: Sign Name Clear